ArticleBlood neoplasia2026

Ten-day decitabine vs "3+7" in patients with AML aged ≥60 years: long-term results of the randomized phase 3 EORTC trial AML21.

Michael Lübbert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.